Triple-Negative Breast Cancer Brain Metastasis: A Comprehensive Review of Epidemiology, Molecular Pathobiology, and Therapeutic Frontiers
Cancers · 07.04.2026 · 18 (7) · 1179
DOI: 10.3390/cancers18071179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.04.2026. Verfasst von Hongli Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, S…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Natural Science Foundation, Shenzhen People's Hospital Physician Scientist Training "Five Three" Program, Shenzhen People’s Hospital Physician Scientist Training “Five Three” Program.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is associated with a high risk of brain metastases (BMs). Although systemic therapies have improved extracranial disease control, the central nervous system (CNS) remains less accessible to numerous agents. As a result, this limited drug penetration makes brain metastases (BMs) remain common in TNBC, which are a leading cause of serious symptoms. This review summarizes recent key advances in triple-negative breast cancer brain metastases (TNBC-BMs), including epidemiology, prognostic stratification, biological mechanisms of CNS tropism and treatment resistance, and evolving management strategies. We discuss potential mechanisms of brain colonization, including the FOXC1-CXCR4 axis, ST6GALNAC5-related interactions with the blood–brain barrier (BBB), and the bidirectional crosstalk between metastatic cells and the brain microenvironment, particularly astrocytes and microglia. Furthermore, we evaluate the evolving clinical management, emphasizing the transition from whole-brain radiotherapy (WBRT) toward more selective local approaches such as stereotactic radiotherapy (SRS) and hippocampal sparing techniques. Concurrently, we examine the integration of CNS active systemic therapy across specific molecular subsets. This review systematically distinguishes standard-of-care interventions from investigational strategies, ultimately underscoring critical evidence gaps within the TNBC-BM landscape.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518000, China.
- China Unicom Digital Intelligence Medical Technology Co., Ltd., Guangzhou 510320, China.
ORCID-Profile: Hongli Yang, Guixiang Liao
Förderung
- Shenzhen Natural Science Foundation
- Shenzhen People's Hospital Physician Scientist Training "Five Three" Program
- Shenzhen People’s Hospital Physician Scientist Training “Five Three” Program
Zitieren
APA
Yang, H., Zhao, Y., Wang, Y., Ma, X., Ling, J., Zeng, X., Li, Z., & Liao, G. (2026). Triple-Negative Breast Cancer Brain Metastasis: A Comprehensive Review of Epidemiology, Molecular Pathobiology, and Therapeutic Frontiers. Cancers, 18(7), 1179. https://doi.org/10.3390/cancers18071179
Vancouver
Yang H, Zhao Y, Wang Y, Ma X, Ling J, Zeng X, et al. Triple-Negative Breast Cancer Brain Metastasis: A Comprehensive Review of Epidemiology, Molecular Pathobiology, and Therapeutic Frontiers. Cancers. 2026;18(7):1179. doi:10.3390/cancers18071179
BibTeX
@article{Yang2026,
author = {Yang, Hongli and Zhao, Yang and Wang, Yue and Ma, Xiaoyuan and Ling, Jinmei and Zeng, Xianyi and Li, Zihuang and Liao, Guixiang},
title = {Triple-Negative Breast Cancer Brain Metastasis: A Comprehensive Review of Epidemiology, Molecular Pathobiology, and Therapeutic Frontiers},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1179},
doi = {10.3390/cancers18071179}
}
EUVIMED